INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32901, 23399, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32902, 25459, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32903, 25460, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32904, 69, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32905, 70, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32906, 11931, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32907, 11932, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32908, 23398, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32909, 23399, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32910, 25459, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32911, 25460, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32912, 69, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32913, 70, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32914, 11931, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32915, 11932, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32916, 23398, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32917, 23399, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32918, 25459, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32919, 25460, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32920, 69, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32921, 70, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32922, 11931, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32923, 11932, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32924, 23398, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32925, 23399, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32926, 25459, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32927, 25460, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32928, 69, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32929, 70, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32930, 11931, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32931, 11932, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32932, 23398, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32933, 23399, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32934, 25459, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32935, 25460, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32936, 69, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32937, 70, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32938, 11931, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32939, 11932, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32940, 23398, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32941, 23399, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32942, 25459, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32943, 25460, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32944, 69, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32945, 70, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32946, 11931, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32947, 11932, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32948, 23398, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32949, 23399, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32950, 25459, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32951, 25460, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32952, 69, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32953, 70, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32954, 11931, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32955, 11932, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32956, 23398, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32957, 23399, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32958, 25459, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32959, 25460, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32960, 0, 'Bexarotene', 'Cataract', 'The use of bexarotene may cause new cataracts or worsening of previous cataracts.  It is recommended to monitor closely for the development of any visual difficulties and to have an appropriate ophthalmologic evaluation.  Exercise caution when using this agent in patients with a history of cataracts.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32961, 0, 'Bexarotene', 'Diabetes Mellitus', 'The use of bexarotene may cause hypoglycemia in diabetic patients.  It is recommended to measure baseline blood glucose levels and to keep monitoring them closely during treatment.  Exercise caution when using this agent in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32962, 0, 'Bexarotene', 'Hyperlipidemias', 'The use of bexarotene may cause elevations in lipids.  It is recommended to monitor lipid levels closely and to obtain a fasting blood lipid reading at baseline and weekly until lipid response to the drug is established.  Exercise caution when using this agent in patients with hyperlipidemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32963, 0, 'Bexarotene', 'Hypothyroidism', 'The use of bexarotene may cause hypothyroidism.  It is recommended to consider thyroid hormone supplementation in patients with hypothyroidism, to obtain baseline thyroid function tests, and to closely monitor patients during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32964, 0, 'Bexarotene', 'Liver Diseases', 'In vitro studies suggest that cytochrome P450 3A4 is the major cytochrome P450 responsible for formation of the oxidative metabolites and that the oxidative metabolites may be glucuronidated.  It is recommended to monitor for signs of toxicity due to increased drug exposure if bexarotene is used in patients with hepatic impairment as these patients are expected to have a decreased drug clearance.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32965, 0, 'Bexarotene', 'Neutropenia', 'The use of bexarotene causes neutropenia.  Neutropenia is reversible after dose reduction or discontinuation of treatment.  Care should be exercised in patients at risk.  It is recommended to obtain complete blood counts at baseline and periodically during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32966, 0, 'Bexarotene', 'Pancreatitis', 'Pancreatitis, including a fatal case, has occurred in patients receiving bexarotene.  It is recommended to monitor for pancreatitis and to interrupt treatment if pancreatitis is suspected.  Close monitoring is recommended in patients who have risk factors for pancreatitis, such as high alcohol consumption, uncontrolled diabetes or hyperlipidemia, and prior pancreatitis, as these patients might be at greater risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32967, 0, 'Ziconotide', 'Infections', 'The use of ziconotide is contraindicated in patients with any other concomitant treatment or medical condition that would render intrathecal administration hazardous.  Contraindications to the use of intrathecal analgesia include the presence of infection at the microinfusion injection site, uncontrolled bleeding diathesis, and spinal canal obstruction that impairs circulation of cerebrospinal fluid.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32968, 0, 'Ziconotide', 'Psychotic Disorders', 'The use of ziconotide is contraindicated in patients with a preexisting history of psychosis.  Severe psychiatric symptoms and neurological impairment may occur during therapy with ziconotide.  It is recommended to monitor all patients for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness during treatment with ziconotide.  Discontinue therapy with ziconotide in the event of serious neurological or psychiatric signs or symptoms.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32969, 3933, 'Botulinum toxin type A', 'Lactose Intolerance', 'Dysport (brand of abobotulinumtoxinA) may contain trace amounts of cow''s milk protein.  Patients known to be allergic to cow''s milk protein should not be treated with this product.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32970, 15453, 'Botulinum toxin type A', 'Lactose Intolerance', 'Dysport (brand of abobotulinumtoxinA) may contain trace amounts of cow''s milk protein.  Patients known to be allergic to cow''s milk protein should not be treated with this product.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32971, 30217, 'Botulinum toxin type A', 'Lactose Intolerance', 'Dysport (brand of abobotulinumtoxinA) may contain trace amounts of cow''s milk protein.  Patients known to be allergic to cow''s milk protein should not be treated with this product.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32972, 3933, 'Botulinum toxin type A', 'Neuromuscular Diseases', 'Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise.  Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin.  Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise.  Patients treated with botulinum toxin may require immediate medical attention should they develop these complications.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32973, 15453, 'Botulinum toxin type A', 'Neuromuscular Diseases', 'Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise.  Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin.  Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise.  Patients treated with botulinum toxin may require immediate medical attention should they develop these complications.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32974, 30217, 'Botulinum toxin type A', 'Neuromuscular Diseases', 'Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise.  Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin.  Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise.  Patients treated with botulinum toxin may require immediate medical attention should they develop these complications.  Caution is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32975, 3933, 'Botulinum toxin type A', 'Infections', 'Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32976, 15453, 'Botulinum toxin type A', 'Infections', 'Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32977, 30217, 'Botulinum toxin type A', 'Infections', 'Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32978, 3933, 'Botulinum toxin type A', 'Urinary Tract Infections', 'Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32979, 15453, 'Botulinum toxin type A', 'Urinary Tract Infections', 'Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32980, 30217, 'Botulinum toxin type A', 'Urinary Tract Infections', 'Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32981, 3933, 'Botulinum toxin type A', 'Glaucoma, Angle-Closure', 'Xeomin (brand of incobotulinumtoxinA), a botulinum toxin product for the treatment of blepharospasm should be used with caution in patients at risk of developing narrow angle glaucoma.  The anticholinergic effects of botulinum toxin products can reduce blinking and lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.  To prevent ectropion, it is recommended that botulinum toxin products should not be injected into the medial lower eyelid area.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32982, 15453, 'Botulinum toxin type A', 'Glaucoma, Angle-Closure', 'Xeomin (brand of incobotulinumtoxinA), a botulinum toxin product for the treatment of blepharospasm should be used with caution in patients at risk of developing narrow angle glaucoma.  The anticholinergic effects of botulinum toxin products can reduce blinking and lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.  To prevent ectropion, it is recommended that botulinum toxin products should not be injected into the medial lower eyelid area.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32983, 30217, 'Botulinum toxin type A', 'Glaucoma, Angle-Closure', 'Xeomin (brand of incobotulinumtoxinA), a botulinum toxin product for the treatment of blepharospasm should be used with caution in patients at risk of developing narrow angle glaucoma.  The anticholinergic effects of botulinum toxin products can reduce blinking and lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.  To prevent ectropion, it is recommended that botulinum toxin products should not be injected into the medial lower eyelid area.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32984, 1593, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32985, 1595, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32986, 1598, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32987, 1606, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32988, 1607, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32989, 1609, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32990, 1793, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32991, 2019, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32992, 2973, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32993, 2975, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32994, 2977, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32995, 11893, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32996, 15335, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32997, 15339, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32998, 15340, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32999, 15341, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33000, 15347, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
